{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:56:00Z","timestamp":1780581360428,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000983","name":"Mary Kay Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000983","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.sapharm.2020.12.010","type":"journal-article","created":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T02:05:08Z","timestamp":1608343508000},"page":"1841-1846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Deprescribing anticholinergic medication in the community mental health setting: A quality improvement initiative"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0762-4054","authenticated-orcid":false,"given":"Jessica M.","family":"Gannon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3863-7758","authenticated-orcid":false,"given":"Ana","family":"Lupu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaspreet","family":"Brar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0880-5789","authenticated-orcid":false,"given":"Myranda","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0668-3335","authenticated-orcid":false,"given":"Susanna","family":"Zawacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2572-5289","authenticated-orcid":false,"given":"Kevin","family":"Carl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1107-2854","authenticated-orcid":false,"given":"K. N.Roy","family":"Chengappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sapharm.2020.12.010_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ajp.2019.08.010","article-title":"Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: finding of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey","volume":"45","author":"Dong","year":"2019","journal-title":"Asian Journal of Psychiatry"},{"issue":"1","key":"10.1016\/j.sapharm.2020.12.010_bib2","doi-asserted-by":"crossref","first-page":"18m12246","DOI":"10.4088\/JCP.18m12246","article-title":"Prevalence of and risk factors for extrapyramidal side effects of antipsychotics: results from the national FACE-SZ cohort","volume":"80","author":"Misdrahi","year":"2019","journal-title":"J Clin Psychiatr"},{"key":"10.1016\/j.sapharm.2020.12.010_bib3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.psychres.2017.05.033","article-title":"Nielsen J Frequency and correlates of anticholinergic use among patients with schizophrenia in Denmark: a Nation-wide pharmacoepidemiological study","volume":"255","author":"Pristed","year":"2017","journal-title":"Psychiatr Res"},{"key":"10.1016\/j.sapharm.2020.12.010_bib4","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.sapharm.2020.12.010_bib5","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1176\/appi.ajp.2013.12101339","article-title":"Clinical phenotypes of psychosis in the bipolar-schizophrenia Network on intermediate phenotypes (B-snip)","volume":"170","author":"Tamminga","year":"2013","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.sapharm.2020.12.010_bib6","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1192\/bjp.156.3.412","article-title":"Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statements. World Health Organization heads of centers collaborating in WHO coordinated studies on biological aspects of mental illness","volume":"156","author":"World Health Organization","year":"1990","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.sapharm.2020.12.010_bib7","series-title":"Drug-Induced Dysfunction in Psychiatry: Diagnosis and Treatment","first-page":"173","article-title":"Anticholinergic drug-induced dysfunction","author":"McEvoy","year":"1992"},{"key":"10.1016\/j.sapharm.2020.12.010_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0920-9964(90)90045-9","article-title":"Effects of anticholinergic medication on memory in schizophrenia","volume":"3","author":"Strauss","year":"1990","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.sapharm.2020.12.010_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/MLR.0b013e3181ef9a7e","article-title":"How is medication prescribing ceased? A systematic review","volume":"49","author":"Ostini","year":"2011","journal-title":"Med Care"},{"issue":"9","key":"10.1016\/j.sapharm.2020.12.010_bib11","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1177\/0269881112447988","article-title":"Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment?","volume":"26","author":"Desmarais","year":"2012","journal-title":"J Psychopharmacol"},{"issue":"8","key":"10.1016\/j.sapharm.2020.12.010_bib12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/j.1552-4604.1991.tb03775.x","article-title":"Prophylactic antiparkinson drug use: II. Withdrawal after long-term maintenance therapy","volume":"31","author":"Lavin","year":"1991","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.sapharm.2020.12.010_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/2045125314553611","article-title":"Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia","volume":"4","author":"Desmarais","year":"2014","journal-title":"Ther Adv Psychopharmacol"},{"issue":"9","key":"10.1016\/j.sapharm.2020.12.010_bib14","doi-asserted-by":"crossref","first-page":"e1270","DOI":"10.4088\/JCP.16m11269","article-title":"Reducing anticholinergic medication burden in patients with psychotic or bipolar disorders","volume":"78","author":"Lupu","year":"2017","journal-title":"J Clin Psychiatr"},{"key":"10.1016\/j.sapharm.2020.12.010_bib15","doi-asserted-by":"crossref","DOI":"10.12788\/acp.0019","article-title":"Less is more: deprescribing anticholinergic medications in persons with severe mental illness","author":"Lupu","year":"2021","journal-title":"Ann Clin Psychiatr"},{"issue":"11","key":"10.1016\/j.sapharm.2020.12.010_bib16","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jamda.2018.06.021","article-title":"Deprescribing medications for chronic diseases management in primary care settings: a systematic review of randomized controlled trials","volume":"19","author":"Dills","year":"2018","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"10.1016\/j.sapharm.2020.12.010_bib17","first-page":"108","article-title":"Clinical pharmacists as allied health care providers to psychiatric patients","volume":"2","author":"Gray","year":"1979","journal-title":"Contemp Pharm Pract"},{"issue":"6","key":"10.1016\/j.sapharm.2020.12.010_bib18","first-page":"643","article-title":"The cost-effectiveness of a clinical pharmacy service in an outpatient mental health clinic","volume":"40","author":"Lobeck","year":"1989","journal-title":"Hosp Community Psychiatry"},{"key":"10.1016\/j.sapharm.2020.12.010_bib19","series-title":"Measuring the Effectiveness of Benzodiazepine Prescriptions Control in Community Setting Using Prescription Drug Monitoring Program (PDMP)","author":"Agrawal","year":"2020"},{"key":"10.1016\/j.sapharm.2020.12.010_bib20","unstructured":"Two Part CME-accredited series of deprescribing anticholinergic medications in patients with severe mental illness Part 1: background and overview of an interventional pilot program kadiamada N. Chengappa, MD, and Ana Lupu, PharmD, review anticholinergic medications and side effects that are associated with them, including peripheral and central effects. Part 2: stories from the clinic \u2013 patient cases and review of barriers and predictors of success Kadiamada N. Chengappa, MD, and Jessica M. Gannon, MD, Discuss Predictors and Barriers to Successful Anticholinergic Burden Reduction in Patients with Schizophrenia."},{"issue":"3","key":"10.1016\/j.sapharm.2020.12.010_bib21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/1745509X.4.3.311","article-title":"Impact of anticholinergics on the aging brain: a review and practical application","volume":"4","author":"Boustani","year":"2008","journal-title":"Aging Health"},{"key":"10.1016\/j.sapharm.2020.12.010_bib22","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archpsyc.1972.01750220084016","article-title":"Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics","volume":"26","author":"Klett","year":"1972","journal-title":"Arch Gen Psychiatr"},{"issue":"12","key":"10.1016\/j.sapharm.2020.12.010_bib23","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1176\/ajp.138.12.1567","article-title":"Adverse effects of antiparkinson drug withdrawal","volume":"138","author":"Jellinek","year":"1981","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.sapharm.2020.12.010_bib24","series-title":"Shared Decision-Making in Mental Health Care: Practice, Research, and Future Directions","year":"2010"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741120312353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741120312353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:26:22Z","timestamp":1761557182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551741120312353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1551741120312353"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2020.12.010","relation":{},"ISSN":["1551-7411"],"issn-type":[{"value":"1551-7411","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deprescribing anticholinergic medication in the community mental health setting: A quality improvement initiative","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2020.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}